全文获取类型
收费全文 | 27232篇 |
免费 | 2834篇 |
国内免费 | 578篇 |
专业分类
耳鼻咽喉 | 917篇 |
儿科学 | 238篇 |
妇产科学 | 552篇 |
基础医学 | 2609篇 |
口腔科学 | 216篇 |
临床医学 | 2828篇 |
内科学 | 3072篇 |
皮肤病学 | 213篇 |
神经病学 | 401篇 |
特种医学 | 940篇 |
外科学 | 2132篇 |
综合类 | 2942篇 |
一般理论 | 2篇 |
预防医学 | 1921篇 |
眼科学 | 70篇 |
药学 | 2060篇 |
11篇 | |
中国医学 | 498篇 |
肿瘤学 | 9022篇 |
出版年
2024年 | 30篇 |
2023年 | 527篇 |
2022年 | 995篇 |
2021年 | 1423篇 |
2020年 | 1123篇 |
2019年 | 1584篇 |
2018年 | 1589篇 |
2017年 | 1376篇 |
2016年 | 1055篇 |
2015年 | 1072篇 |
2014年 | 2191篇 |
2013年 | 1977篇 |
2012年 | 1559篇 |
2011年 | 1633篇 |
2010年 | 1282篇 |
2009年 | 1271篇 |
2008年 | 1454篇 |
2007年 | 1244篇 |
2006年 | 1031篇 |
2005年 | 831篇 |
2004年 | 708篇 |
2003年 | 542篇 |
2002年 | 381篇 |
2001年 | 450篇 |
2000年 | 384篇 |
1999年 | 330篇 |
1998年 | 271篇 |
1997年 | 230篇 |
1996年 | 249篇 |
1995年 | 189篇 |
1994年 | 175篇 |
1993年 | 133篇 |
1992年 | 89篇 |
1991年 | 81篇 |
1990年 | 68篇 |
1989年 | 75篇 |
1988年 | 53篇 |
1987年 | 48篇 |
1986年 | 42篇 |
1985年 | 110篇 |
1984年 | 131篇 |
1983年 | 98篇 |
1982年 | 129篇 |
1981年 | 88篇 |
1980年 | 81篇 |
1979年 | 75篇 |
1978年 | 48篇 |
1977年 | 30篇 |
1976年 | 34篇 |
1975年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
5.
6.
Yuxiang Ma Wenfeng Fang Hongyun Zhao Sai Praneeth Bathena Amol Tendolkar Jennifer Sheng Li Zhang 《The oncologist》2021,26(4):e549-e566
Lessons Learned
- The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified.
- The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg/kg and 10 mg/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg/kg and 10 mg/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.
7.
《Transfusion and apheresis science》2022,61(4):103488
The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors or hematologic malignancies were more prone to the infection and had higher morbidity and mortality than the rest of the population. Major signaling pathways have been identified at the intersection of SARS-CoV-2 and cancer cells, often leading to tumor progression or alteration of the tumor response to therapy. The reactivation of oncogenic viruses has also been alluded to in the context and following COVID-19. Paradoxically, certain tumors responded better following the profound infection-induced immune modulation. Unveiling the mechanisms of the virus-tumor cell interactions will lead to a better understanding of the pathophysiology of both cancer progression and virus propagation. It would be challenging to monitor, through the different cancer registries, retrospectively, the response of patients who have been previously exposed to the virus in contrast to those who have not contracted the infection. 相似文献
8.
9.
《Bulletin du cancer》2023,110(2):145-150
10.